Exagen Inc. - Common Stock (XGN)
Competitors to Exagen Inc. - Common Stock (XGN)
Abbott Laboratories ABT -2.09%
Abbott engages in a wider array of medical technology and diagnostics across multiple disease areas, including autoimmune disorders diagnosed through tests similar to those offered by Exagen. Abbott's extensive experience, financial resources, and established market presence in the diagnostics field provide it with a competitive advantage, allowing it to innovate and scale rapidly compared to Exagen's more niche focus.
Horizon Therapeutics plc
Horizon Therapeutics develops treatments for rare and autoimmune diseases and competes with Exagen by offering comprehensive therapeutic solutions, as opposed to pure diagnostics. While Exagen primarily provides laboratory tests to aid in diagnosis and management of diseases like systemic lupus erythematosus, Horizon’s competitive advantage lies in its established product portfolio and ability to market direct therapies to patients.
Myriad Genetics, Inc. MYGN -1.86%
Myriad Genetics competes with Exagen by providing genetic testing services for various diseases, including autoimmune disorders. Both companies are focused on precision medicine, yet Myriad's broader array of genetic tests and its robust market presence allow it to secure a competitive advantage in terms of both recognition and clinical partnerships, potentially leading to more widespread adoption of its products.
Prometheus Biosciences, Inc.
Prometheus Biosciences focuses on precision medicine for autoimmune diseases, which overlaps with Exagen's specialized diagnostic solutions targeting similar patient populations. Both companies utilize advanced biomarker technologies to offer insights into disease mechanisms, but Prometheus leverages a more advanced drug development pipeline for treatment options alongside its diagnostics, potentially giving it an edge in integrated patient care.
Thermo Fisher Scientific Inc. TMO -2.67%
Thermo Fisher offers a broad range of laboratory instruments, reagents, and diagnostic services, including those relevant to autoimmune disease testing. While Exagen specializes in specific diagnostic tests for conditions like lupus, Thermo Fisher's vast resources and product variety give it a significant competitive edge in research, development, and commercialization in the diagnostics space.